COUMARIN 4-METHYLUMBELLIFERONE (4MU) REDUCES THE RESISTANCE TO CONVENTIONAL CHEMOTHERAPY AND THE TUMORIGENIC CAPABILITY OF CD133+ LUNG CANCER CELLS.

PICCIONI, F; FUSCO, M; DÍAZ, MA; GAYET PREISS, F

Buenos Aires

Congreso; Reunión conjunta SAIC, SAI, AAFE, NANOMED AR.; 2021

We could asses that 4Mu 0.25 mM significantly reduces HA expresión in LLC cells.Also, we found that CD133+ LLC cells express higher levels of HA and its receptor CD44 compared to CD133- cells. This indicates a differential expression of HA and CD44 in CSCs.HA synthases HAS2 and HAS3 gene expression by LLC cells were increased by Paclitaxel, while HYAL2 gene expression was reduced, indicating that chemotherapy with this drug may induce HA synthesis. CD44 expression was not altered by Paclitaxel.We observed that chemotherapy with Paclitaxel increases gene expression of CSCs markers, which could be correlated with resistance to treatment. 4Mu in combination with chemotherapy was able to reduce viability, clonogenicity (colony-forming capacity) and tumorigenicty (spheroid formation) of LLC CD133+ cells. The modulation of HA by 4Mu modifies CSCs phenotype, making them more sensitive lo chemotherapy. This strategy could make chemotherapy more effective in NSCLC, and then prevent cancer recurrence.